Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777381 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL23481681 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL16500293 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL23481682 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24583882 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24583918 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL23481684 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24583914 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL22807302 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL29624147 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | claimed |
| US-12048676-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240116850-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267548-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | The Broad Institute Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140654-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BROAD INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140654-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BROAD INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3986412-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | The Broad Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11207278-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11207278-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210169827-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210169827-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257736-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169827-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | MEN1 2707/4885CYP1A2 4870/4885CYP3A4 4871/4885 |
| US-12048676-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | MEN1 2707/4885CYP1A2 4870/4885CYP3A4 4871/4885 |
| US-11207278-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | MEN1 2707/4885CYP1A2 4870/4885CYP3A4 4871/4885 |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | MEN1 2707/4885CYP1A2 4870/4885CYP3A4 4871/4885 |
| US-20240116850-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | ANXA2, PHOSPHO1, CCNB2 | MEN1 595/4885CYP1A2 75/4885CYP3A4 449/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | MEN1 3823/4885CYP1A2 94/4885CYP3A4 62/4885 |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | MEN1 2707/4885CYP1A2 4870/4885CYP3A4 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.